a complete resolution of symptoms and a long-term recovery. 3 , 19 – 25
Ketamine, a noncompetitive NMDA receptor antagonist, may be effective for pain relief in patients with chronic CRPS who are resistant to other therapies as the NMDA receptor is a key component to central sensitization. 24 , 26 – 28 In 1 double-blinded, randomized, controlled trial comparing prolonged low-dose ketamine infusions (mean rate ∼5.2 mcg/kg/min for 4.2 days) to placebo, a significant decrease in pain scores persisted up to 12 weeks in the ketamine group, but patients